InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,235.48
(
-0.60%
)
US TECH 100
18,022.83
(
-1.29%
)
Dow Jones
38,111.48
(
-0.86%
)
Brent Oil
81.95
(
-1.71%
)
Bitcoin
68,362.24
(
1.15%
)
Post# of 111
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Boris the Spider

Send PM Follow Ignore
Followers 59
Posts 2414
Boards Moderated 0
Alias Born 05/18/2013

Boris the Spider

Re: None

Friday, 07/28/2023 12:56:32 PM

Friday, July 28, 2023 12:56:32 PM

Post# of 111
Phase 2 trial for corneal pain. Another market.
OKYO Pharma Plans to Initiate Phase 2 Trial of OK-101 in Neuropathic Corneal Pain (“NCP”) Following Announcement of Clinical Trial Agreement with Tufts Medical Center
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent OKYO News
More OKYO News
InvestorsHub NewsWire

FEATURED Element79 Gold To Provide Summary and Update on Active Exploration Program, Community Relations at RMEC on June 4 • May 30, 2024 1:18 PM

Branded Legacy Secures Exclusive Extraction Partnership with One of the World's Largest Kava Distributors and Producers • BLEG • May 30, 2024 8:30 AM

ECGI Holdings, Inc. Announces $2 Million Debt-to-Equity Conversion • ECGI • May 30, 2024 8:30 AM

North Bay Resources Reports Assays up to >25% Mg, 0.1% Ni, 0.1% Cu, 0.01% Co, 0.3 ppm Pt at Tulameen Platinum Project, British Columbia • NBRI • May 29, 2024 9:03 AM

One World Products, Inc. Issues Shareholder Update • OWPC • May 29, 2024 8:20 AM

Green Leaf Innovations, Inc. Engages Olayinka Oyebola & Co for Two-Year Audit • GRLF • May 28, 2024 8:30 AM

Start posting your company's news
Only $200 per official company press release!